Purpose Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor,
showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III …

Purpose Amrubicin is a synthetic anthracycline with potent topoisomerase II inhibition. This
phase II study was conducted to confirm safety and activity of amrubicin in the treatment of …

Purpose Amrubicin, a new anthracycline agent, and topotecan are both active for previously
treated small-cell lung cancer (SCLC). No comparative study of these agents has been …

Purpose This phase II study evaluated the safety and efficacy of single-agent amrubicin
versus topotecan in patients with small-cell lung cancer (SCLC) sensitive to first-line …

Purpose This multicenter, phase II study was conducted to evaluate the activity of amrubicin,
a topoisomerase II inhibitor, against refractory or relapsed small-cell lung cancer (SCLC) …

According to recent analyses, there was a modest yet significant improvement in median
survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North …

Background Amrubicin, a totally synthetic 9-amino-anthracycline, demonstrated excellent
single-agent activity for extensive-stage small-cell lung cancer (ED-SCLC). The aims of this …

Purpose: This clinical practice guideline, based on a systematic review, evaluates
chemotherapy options for patients with relapsed small cell lung cancer (SCLC). Methods …

Background This trial was designed to prove superiority of irinotecan over etoposide
combined with carboplatin in extensive-disease small-cell lung cancer. Patients and …

Purpose Single-agent intravenous (IV) topotecan is an effective treatment for small-cell lung
cancer (SCLC) after failure of first-line chemotherapy. This open-label, randomized, phase III …